Actively Recruiting
Multiomics Tumor Evolution Model of NSCLC
Led by Peking University People's Hospital · Updated on 2025-04-30
300
Participants Needed
1
Research Sites
245 weeks
Total Duration
On this page
Sponsors
P
Peking University People's Hospital
Lead Sponsor
C
Chinese Academy of Medical Sciences
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.
CONDITIONS
Official Title
Multiomics Tumor Evolution Model of NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 24 18 years old
- Early-stage NSCLC patients underwent radical surgical resection
- Sufficient tumor tissue and blood sample for study use
- Available clinical-pathologic data, imaging data and follow-up date
- Written informed consent
You will not qualify if you...
- History of other malignant tumors
- Evidence of distant metastasis before surgery
- Insufficient tumor tissue or blood sample for study use
- Clinical-pathologic data, imaging data or follow-up date is not available
- Other judgments by the Investigator that the patient should not participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, China
Actively Recruiting
Research Team
K
Kezhong Chen, M.D.
CONTACT
W
Wenxiang Wang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here